Lipocine (LPCN) Stock: Rising On Clinical Data

Lipocine LPCN Stock News

Lipocine Inc (NASDAQ: LPCN) is making a run for the top in the market this morning, and for good reason. The company announced positive top-line results from a key clinical trial.

As you could imagine, the news excited investors who are pushing the stock for the top in the market this morning. Today, we’ll talk about:

  • The clinical data;
  • what we’re seeing from LPCN stock as a result; and
  • what we’ll be watching for ahead.

LPCN Heads Up On Clinical Data

As mentioned above, Lipocine is having a strong start to the trading session this morning after the company announced posiitive clinical data. The data came by way of press release early this morning.

In the release, the company provided 16-week Liver Fat Imaging data following treatment with LPCN 1144. The study was designed to assess LPCN 1144 as a treatment options in non-alcoholic steatohepatitis (“NASH”). At the moment, there are no FDA approved treatments targeting this indication.

In the release, the company said that the treatment demonstrated that 48% of the patients treated had NAFLD resolution. Additionally, 100% of patients that experienced resolution, at least a 35% reduction in liver fat from baseline was observed.

In a statement, Dr. Mahesh Patel, Chairman, President and CEO at LPCN, had the following to offer:

Testosterone deficiency is also known to further exacerbate liver disease symptoms. “We are encouraged by the Liver Fat Study results, especially the extent of the observed NAFLD resolution which improved over eight-week interim results with potential for further improvement upon longer treatmentWe look forward to conducting further clinical testing with LPCN 1144, in biopsy confirmed NASH subjects.

What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Lipocine, the news proved to be overwhelmingly positive.

After all, the strong clinical data shows that the company’s LPCN 1144 asset is progressing well. Moreover, if it reaches approval, it may be the first approved treatment for the NASH indication, offering incredible value to investors.

So, it’s no surprise to see that excited investors are pushing the stock on a run for the top. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:53), LPCN is trading at $2.30 per share after a gain of $0.12 per share or 5.29% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on LPCN. In particular, we’re interested in following the story surrounding the company’s continued work to bring LPCN 1144 as well as the rest of its robust pipeline to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here